OncoMatch/Clinical Trials/NCT06730750
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Is NCT06730750 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including BMS-986490 and Bevacizumab for advanced solid tumors.
Treatment: BMS-986490 · Bevacizumab — This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic cancer therapy (5-FU, irinotecan, oxaliplatin) — metastatic or adjuvant
disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated)
Must have received: anti-PD-1/PD-L1 therapy
must have received and progressed on or after anti-PD-(L)1 therapy, if available
Must have received: standard treatment regimen — advanced or metastatic
must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy)
Cannot have received: therapy targeting CEACAM5
Previously received therapy targeting CEACAM5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- START Midwest · Grand Rapids, Michigan
- John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, New Jersey
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify